The Latest Breaking News from Cantor

Cantor Fitzgerald CEO Howard Lutnick is fast becoming a popular name in talks regarding Donald Trump's Treasury Secretary pick, and while Scott Bessent is still leading on Polymarket, Lutnick is gaining traction after commendations from Elon Musk, RFK Jr. and David Bailey.

With rate cuts on the horizon, here are three stocks poised to benefit, according to analysts.

MicroStrategy is a good stock to own if you are bullish about Bitcoin's long-term prospects. For investors with a higher risk profile, the MSTX ETF might also seem attractive.

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Acreage Holdings, Inc. (OTCQX: ACRDF) reported its financial results on Monday for the third quarter that ended September 30, 2022 (“Q3 2022”).

Jushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF) will announce its financial results for the third quarter before the market opens on Monday, November 14, 2022.

Pablo Zuanic from Cantor Fitzgerald offered an industry update, covering cannabis pricing in Pennsylvania and Florida based on retailers’ menus. “Think of this report as 'food for thought' - we are not adjusting estimates or our investment views,” Zuanic said.

Anshu Jain, Cantor Fitzgerald’s president who was known for his time leading Deutsche Bank traders into the lender’s investment banking heights, died five years after being diagnosed with duodenal cancer. He was 59.

In perhaps a sign that incremental progress on federal cannabis reform is afoot, some Wall Street analysts are increasingly coming around on the idea that reform can happen this year. Cantor Fitzgerald analyst Pablo Zuanic, a noted skeptic on SAFE Banking, now believes the legislation has a real chance of…

Celldex Therapeutics Inc's (NASDAQ:CLDX) shares closed almost 16% down on Friday after releasing Phase 1b study data of barzolvolimab. Cantor says the main reason for stock being down is the four patient adverse events on the generally transient, asymptomatic, and mild neutrophil decreases, noting a single Grade 3 case. One patient had values…